Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in ChinaPfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration Share XPfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in Chinahttps://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
Preparing for the next decade of innovation in immuno-oncologyImmuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic Share XPreparing for the next decade of innovation in immuno-oncologyhttps://pharmaphorum.com/oncology/immuno-oncology-clinicial-trial-market-access/
Gilead poaches oncology expert Quigley from BMSGilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of Share XGilead poaches oncology expert Quigley from BMShttps://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/
AZ joins with Seres to research role of gut microbiome in cancerAstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of Share XAZ joins with Seres to research role of gut microbiome in cancerhttps://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/
Keytruda could get patient-friendly 6 week dosing schedule in EUUS-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week Share XKeytruda could get patient-friendly 6 week dosing schedule in EUhttps://pharmaphorum.com/news/keytruda-could-get-patient-friendly-6-week-dosing-schedule-in-eu/
Celgene signs brace of immuno-oncology deals with US biotechsDespite a looming takeover by Bristol-Myers Squibb, Celgene hasn’t stopped making pipeline-boosting deals. It’s just added two more Share XCelgene signs brace of immuno-oncology deals with US biotechshttps://pharmaphorum.com/news/celgene-signs-brace-of-immuno-oncology-deals-with-us-biotechs/
Frazier to stay on as Merck CEO, as company axes retirement policyMerck & Co’s CEO Ken Frazier has received the strongest possible backing from the company’s board, after it Share XFrazier to stay on as Merck CEO, as company axes retirement policyhttps://pharmaphorum.com/news/frazier-to-stay-on-as-merck-ceo-as-company-axes-retirement-policy/
Latest lung cancer data could open new avenue for Roche’s TecentriqRoche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it Share XLatest lung cancer data could open new avenue for Roche’s Tecentriqhttps://pharmaphorum.com/news/latest-lung-cancer-data-could-open-new-avenue-for-roches-tecentriq/
Communication problems holding back new cancer treatmentsCancer immunotherapy is revolutionising oncology – but the Havas Lynx Group’s chief medical officer Vernon Bainton argues that the incredible progress is Share XCommunication problems holding back new cancer treatmentshttps://pharmaphorum.com/oncology/communication-problems-holding-back-new-cancer-treatments/
